{"resourceType": "Group", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"], "versionId": "70", "lastUpdated": "2025-03-20T18:40:09.616Z"}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to", "extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}]}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "236949", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "assigner": {"display": "Computable Publishing LLC"}}], "title": "SGLT2 inhibitors Group in Adults with type 2 diabetes", "status": "active", "description": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ExposureGroup", "display": "ExposureGroup"}]}}], "type": "person", "membership": "enumerated", "combinationMethod": "all-of", "characteristic": [{"description": "inclusion in Adults with type 2 diabetes", "code": {"text": "Member of"}, "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adults with type 2 diabetes and CVD and CKD", "reference": "Group/236947"}, "exclude": false}, {"description": "received SGLT2 inhibitors", "code": {"text": "Exposed to"}, "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors", "reference": "Group/236769"}, "exclude": false}], "url": "https://fevir.net/resources/Group/236949", "id": "236949", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}]}